

# Canadian Pricing and Reimbursement: Understanding the Biggest Hurdles in the Payer Landscape

Richard Macaulay

Global Pricing & Market Access, PRECISIONAdvisors, London, UK




## Background



Key national stakeholders in the Canadian pricing and reimbursement landscape are:

	CADTH	PMPRB	pCPA
Full name	Canadian Agency for Drugs and Technologies in Health	Patented Medicine Prices Review Board	pan-Canadian Pharmaceutical Alliance
Established	1989	1980	2010
Role	evaluates the clinical and economic benefits of new therapies	sets a national ceiling price for new therapies	collectively negotiate rebates off the list price for public plans


## Aims and methods



## Results (1): PMPRB & CADTH



## Results (2): pCPA



## Conclusions

Based upon this assessment, the substantial hurdles to clear for new therapies in Canada are the CADTH assessment and the pCPA negotiations. To date, the PMPRB has rarely (<5% cases) issued VCUs to regulate drug prices

However, significant PMPRB reforms are due to be implemented from 01-JUL-2021, including changing the reference basket of countries and allowing economic evaluations, significantly increasing the PMPRB's impact